VRC 314: A Phase 1, Open-Label, Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Durability of Protection Following Intravenous and Intramuscular Administration of PFSPZ Vaccine in Malaria-Naive Adults

Trial Profile

VRC 314: A Phase 1, Open-Label, Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Durability of Protection Following Intravenous and Intramuscular Administration of PFSPZ Vaccine in Malaria-Naive Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2017

At a glance

  • Drugs Malaria vaccine live attenuated-Sanaria (Primary) ; Malaria vaccine live attenuated-Sanaria (Primary)
  • Indications Falciparum malaria
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VRC 314
  • Most Recent Events

    • 09 Sep 2016 Status changed from recruiting to completed.
    • 02 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
    • 02 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top